Skizofrénia: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• NMDA 9
• BDNF 0
• GLP-1 1
• mTOR 0
• AKT 0
• PI3K 0
• TNF 0
• ERK 0
• IL-6 0
• NLRP3 0
• PPAR 0
• NRF2 0
• AMPK 0
• IL-17 0
• IL-23 1
• MAPK 0
• MAPT 0
• BACE1 0
• BCL-2 0
• C9orf72 0
• CD20 0
• COX-2 0
• DMD 0
• EGFR 0
• FOXP3 0
• FTO 0
• HMGB1 0
• IDO1 0
• IL-1 0
• JAK 0
• MMP-9 0
• PCSK9 0
• PDE4 0
• SCN2A 0
• SGLT2 0
• SIRT1 0
• STAT3 0
• TFEB 0
• TREM2 0
• VEGF 0

1+ intézményből 1, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIMH · F30

  Neural Correlates of Memory-Based Generalization in Humans

  University of California at Davis· Davis, Egyesült Államok· 43 749 USD awarded in fiscal year 2026· until 2030. szept.

• NIH NIMH · F31

  Modeling clozapine response in treatment resistant schizophrenia using cortical organoids

  Univ of North Carolina Chapel Hill· Chapel Hill, Egyesült Államok· 44 404 USD awarded in fiscal year 2026· until 2029. szept.

• NIH NEI · F31

  Neural and Computational Mechanisms of Subjective Perceptual Precision

  Boston University (Charles River Campus)· Boston, Egyesült Államok· 40 220 USD awarded in fiscal year 2026· until 2029. szept.

• NIH NIA · R44

  Long-acting Injectable Brexpiprazole for Agitation in Alzheimer's Dementia

  Auritec Pharmaceuticals, Inc.· Pasadena, Egyesült Államok· 1 029 519 USD awarded in fiscal year 2026· until 2028. máj.

• NIH NIA · R01

  Proof of Concept (Phase 0) Study of Clinical Trial Outcomes and Biomarkers in Early Stage Dementia with Lewy Bodies

  University of Miami School of Medicine· Coral Gables, Egyesült Államok· 644 011 USD awarded in fiscal year 2026· until 2031. máj.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Misinterpreting reality: Investigating the neural basis of hallucinatory percepts (MISHAPS)

  University College London· London, Egyesült Királyság· EU contribution 260 348 EUR· until 2029. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Interneuron subtype-specific control of hippocampal memory encoding and retrieval (INSPIRE)

  Universitaetsklinikum Freiburg· Freiburg, Németország· EU contribution 202 125 EUR· until 2029. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Continuous Estrogen Monitoring Patch (EstroPatch)

  Katholieke Universiteit Leuven· Leuven, Belgium· EU contribution 321 301 EUR· until 2030. máj.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Cannabis Neurobiology And Schizophrenia Risk in Youth: A Multi-Omics Translation (CANARY)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 1 500 000 EUR· until 2031. dec.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Thalamic Nuclei Connectivity in the Psychosis Continuum: Parsing Clinical Heterogeneity and Individual Trajectories (THALAMIND)

  Universite de Geneve· Geneve, Svájc· EU contribution 469 989 EUR· until 2029. dec.· 2 countries

10 of 1117 running projects, newest first. Listed amounts together: 651,8 M USD + 125,4 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder

  NCT06939088· Anders Fink-Jensen, MD, DMSci· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 8
• Organoids 5
• Mendelian Randomization Analysis 70
• CRISPR-Cas Systems 2
• Gene Expression Profiling 45
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 3
• Exome Sequencing 4
• Proteomics 30
• Metabolomics 24
• Mass Spectrometry 7
• Flow Cytometry 1
• Immunohistochemistry 8
• Positron-Emission Tomography 30
• Magnetic Resonance Imaging 385
• Machine Learning 81
• Deep Learning 17
• Cohort Studies 169
• Genome-Wide Association Study 174

• NeuroBase: A Web-Based Transcriptomic Resource and R Package for Cross-Disorder Analysis of Neurodegenerative and Neuropsychiatric Diseases.

  Mol Neurobiol, 2026. nov.

• Somatostatin expression is associated with mitochondrial-related gene expression in a brain region-specific manner: Evidence from human transcriptomic analysis.

  Behav Brain Res, 2026. aug.

• Transcriptomic characteristics of plasma from Chinese ethnic minority patients with major depressive disorder.

  Transl Psychiatry, 2026. aug.

• Analysis of gene co-expression connectivity dynamics implicates aberrant neuron-oligodendroglia interactions in schizophrenia.

  Nat Commun, 2026. júl.

• Identification of hub genes involved in early-onset schizophrenia: from genetic susceptibility to predicted regulated gene expression.

  Mol Psychiatry, 2026. júl.

• Transcriptomic signatures and neural cell composition in schizophrenia iPSC-derived neuron cultures.

  Cells Dev, 2026. júl.

• Blood-based biomarker discovery through integrative transcriptomic and miRNA network analyses in schizophrenia, major depressive disorder, and bipolar disorder.

  Comput Biol Chem, 2026. jún.

• Co-expression-based models improve eQTL predictions for transcriptome-wide association studies and highlight new schizophrenia-associated genes.

  Nat Genet, 2026. jún.

• Developmentally dynamic, non-convergent transcriptomic profiles in CNV models for schizophrenia risk.

  Mol Psychiatry, 2026. jún.

• Integrative Multiomics Analysis Identifies DKK3 as a Germline Susceptibility-Related Regulator of Risperidone Response and Metabolic Risk in Schizophrenia.

  Hum Mutat, 2026. jún.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.